S
Santiago Viteri
Researcher at University of Texas Health Science Center at San Antonio
Publications - 152
Citations - 4752
Santiago Viteri is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 29, co-authored 125 publications receiving 3151 citations. Previous affiliations of Santiago Viteri include University of Barcelona & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik,E. Felip,Remi Veillon,Hiroshi Sakai,Alexis B. Cortot,Marina Chiara Garassino,J. Mazieres,Santiago Viteri,Hélène Senellart,Jan van Meerbeeck,Jo Raskin,Niels Reinmuth,Pierfranco Conte,Dariusz M. Kowalski,Byoung Chul Cho,Jyoti D. Patel,Leora Horn,Frank Griesinger,Ji Youn Han,Young Chul Kim,Gee Chen Chang,Chen Liang Tsai,James Chih-Hsin Yang,Yuh Min Chen,Egbert F. Smit,Anthonie J. van der Wekken,Terufumi Kato,Dilafruz Juraeva,Christopher Stroh,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,J. Heymach,Xiuning Le +34 more
TL;DR: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients, and adverse events led to permanent discontinuation of tEPotinib in 11% of the patients.
Journal ArticleDOI
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio,Ernest Nadal,A. Insa,M.-R. García-Campelo,Joaquín Casal-Rubio,Manuel Domine,Margarita Majem,Delvys Rodriguez-Abreu,Alex Martinez-Marti,Javier de Castro Carpeño,Manuel Cobo,Guillermo López Vivanco,Edel del Barco,Reyes Bernabe Caro,Nuria Viñolas,Isidoro Barneto Aranda,Santiago Viteri,E. Pereira,Ana Royuela,M. Casarrubios,Clara Salas Antón,Edwin Roger Parra,Ignacio I. Wistuba,Virginia Calvo,Raquel Laza-Briviesca,Atocha Romero,Bartomeu Massuti,Alberto Cruz-Bermúdez +27 more
TL;DR: The results support the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with resectable stage IIIA NSCLC and could change the perception of locally advanced lung cancer as a potentially lethal disease to one that is curable.
Journal ArticleDOI
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Rafael Rosell,Miguel Angel Molina,Carlota Costa,Sara Simonetti,Anna Gimenez-Capitan,Jordi Bertran-Alamillo,Clara Mayo,Teresa Moran,Pedro Mendez,Felipe Cardenal,Dolores Isla,Mariano Provencio,Manuel Cobo,A. Insa,Rosario García-Campelo,Noemi Reguart,Margarita Majem,Santiago Viteri,Enric Carcereny,R. Porta,Bartomeu Massuti,Cristina Queralt,Itziar de Aguirre,Jose Miguel Sanchez,Maria Sanchez-Ronco,Jose Luis Mate,Aurelio Ariza,Susana Benlloch,Jose Javier Sanchez,Trever G. Bivona,Charles L. Sawyers,Miquel Taron +31 more
TL;DR: Low BRCA1 levels neutralized the negative effect of the T790M mutation and were associated with longer progression-free survival to erlotinib.
Journal ArticleDOI
Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
Keunchil Park,Eric B. Haura,Natasha B. Leighl,Paul Mitchell,Catherine A. Shu,Nicolas Girard,Santiago Viteri,Ji-Youn Han,Sang-We Kim,Chee Khoon Lee,Joshua K. Sabari,Alexander I. Spira,Tsung-Ying Yang,Dong Wan Kim,Ki Hyeong Lee,Rachel E. Sanborn,Jose Manuel Trigo,Koichi Goto,Jong Seok Lee,James Chih-Hsin Yang,Ramaswamy Govindan,Joshua Bauml,Pilar Garrido,Matthew G Krebs,Karen L. Reckamp,John Xie,J.C. Curtin,Nahor Haddish-Berhane,A. Roshak,Dawn Millington,Patricia Lorenzini,Meena Thayu,Roland Elmar Knoblauch,Byoung Chul Cho +33 more
TL;DR: PURPOSENon-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors as mentioned in this paper.
Journal ArticleDOI
The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Carlota Costa,Miguel Angel Molina,Ana Drozdowskyj,Ana Giménez-Capitán,Jordi Bertran-Alamillo,Niki Karachaliou,Radj Gervais,Bartomeu Massuti,Jia Wei,Teresa Moran,Margarita Majem,Enriqueta Felip,Enric Carcereny,Rosario García-Campelo,Santiago Viteri,Miquel Taron,Mayumi Ono,Petros Giannikopoulos,Trever G. Bivona,Rafael Rosell +19 more
TL;DR: Low-level pretreatment T790M mutations can frequently be detected and can be used for customizing treatment with T790m-specific inhibitors and can potentially be used as a biomarker of survival in EGFR-mutant NSCLC and for synthetic lethality therapies.